Iridex to Report Second Quarter 2024 Financial Results on August 8, 2024
Iridex (NASDAQ: IRIX), a leader in laser-based medical systems for glaucoma and retinal diseases, has announced its plan to release second quarter 2024 financial results on August 8, 2024, after market close. The company will also provide a business update during a conference call scheduled for the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors can join the call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) using conference ID: 9156340. A live and recorded webcast will be available on the company's website at www.iridex.com under the 'Investors' section's 'Event Calendar' page.
Iridex (NASDAQ: IRIX), leader nei sistemi medici basati su laser per il glaucoma e le malattie retiniche, ha annunciato il suo piano di pubblicare i risultati finanziari del secondo trimestre 2024 il 8 agosto 2024, dopo la chiusura del mercato. L'azienda fornirà anche un aggiornamento sulle attività durante una conference call programmata per lo stesso giorno alle 14:00 PT / 17:00 ET.
Gli investitori possono partecipare alla chiamata componendo il numero (646) 307-1963 (per chiamate nazionali) o (800) 715-9871 (per chiamate internazionali) utilizzando l'ID conferenza: 9156340. Un webcast in diretta e registrato sarà disponibile sul sito web dell'azienda all'indirizzo www.iridex.com nella sezione 'Investitori' nella pagina 'Calendario Eventi'.
Iridex (NASDAQ: IRIX), líder en sistemas médicos basados en láser para el glaucoma y enfermedades de la retina, ha anunciado su plan de publicar los resultados financieros del segundo trimestre de 2024 el 8 de agosto de 2024, después del cierre del mercado. La compañía también proporcionará una actualización comercial durante una llamada en conferencia programada para el mismo día a las 2:00 p.m. PT / 5:00 p.m. ET.
Los inversores pueden unirse a la llamada marcando (646) 307-1963 (nacional) o (800) 715-9871 (internacional) utilizando el ID de conferencia: 9156340. Se dispondrá de una transmisión en vivo y grabada en el sitio web de la compañía en www.iridex.com en la sección 'Inversores' bajo la página 'Calendario de Eventos'.
Iridex (NASDAQ: IRIX)는 녹내장 및 망막 질환을 위한 레이저 기반의 의료 시스템의 선두주자로, 2024년 2분기 재무 결과를 2024년 8월 8일 시장 종료 후 발표할 계획을 발표했습니다. 또한 같은 날 오후 2시 PT / 오후 5시 ET에 예정된 전화 회의에서 사업 업데이트를 제공할 것입니다.
투자자는 (646) 307-1963 (국내) 또는 (800) 715-9871 (해외)로 전화하여 회의 ID: 9156340을 사용하여 호출에 참여할 수 있습니다. 회사 웹사이트 www.iridex.com의 '투자자' 섹션 내 '이벤트 캘린더' 페이지에서 실시간 및 녹화된 웹 캐스트를 이용할 수 있습니다.
Iridex (NASDAQ: IRIX), un leader dans les systèmes médicaux basés sur le laser pour le glaucome et les maladies rétiniennes, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le 8 août 2024, après la clôture des marchés. L'entreprise fournira également une mise à jour commerciale lors d'une conférence téléphonique prévue le même jour à 14h00 PT / 17h00 ET.
Les investisseurs peuvent participer à l'appel en composant le (646) 307-1963 (national) ou le (800) 715-9871 (international) en utilisant l'identifiant de conférence : 9156340. Un webinaire en direct et enregistré sera disponible sur le site web de l'entreprise à l'adresse www.iridex.com dans la section 'Investisseurs' sur la page 'Calendrier des événements'.
Iridex (NASDAQ: IRIX), ein führendes Unternehmen im Bereich laserbasierter medizinischer Systeme für Glaukom und Netzhauterkrankungen, hat angekündigt, die finanziellen Ergebnisse für das zweite Quartal 2024 am 8. August 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 14:00 Uhr PT / 17:00 Uhr ET auch ein Update zur Geschäftslage während einer Telefonkonferenz bereitstellen.
Investoren können an dem Call teilnehmen, indem sie (646) 307-1963 (national) oder (800) 715-9871 (international) wählen und die Konferenz-ID: 9156340 verwenden. Ein Live- und aufgezeichnetes Web-Event wird auf der Unternehmenswebsite unter www.iridex.com im Bereich 'Investoren' auf der Seite 'Veranstaltungskalender' verfügbar sein.
- None.
- None.
MOUNTAIN VIEW, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter 2024 and provide a business update after the close of trading on Thursday, August 8, 2024.
The Company’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (646) 307-1963 for domestic callers or (800) 715-9871 for international callers, using conference ID: 9156340. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex (IRIX) release its Q2 2024 financial results?
What time is Iridex's (IRIX) Q2 2024 earnings conference call?
How can investors access Iridex's (IRIX) Q2 2024 earnings call?
What does Iridex (IRIX) specialize in?
